Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

IMMUNE PHARMACEUTICALS, INC.

(IMNPQ)
SummaryQuotesChartsNewsCompany 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Motion for Asset Sale Approved for Immune Pharmaceuticals, Inc.

10/27/2020 | 11:00pm EST

The US Bankruptcy Court gave an order approving the sale of the certain assets of Immune Pharmaceuticals, Inc. on October 28, 2020. The debtor has been authorized to sell its certain assets to Discover Growth Fund, LLC for a purchase price of $0.18 million in cash pursuant to the asset purchase agreement. The seller and the buyer intend to close the sale as soon as reasonably practicable and, in any event, on or prior to 75 days from the date of execution of the APA.


ę S&P Capital IQ 2020
All news about IMMUNE PHARMACEUTICALS, INC.
04/13IMMUNE PHARMACEUTICALS INC : Completion of Acquisition or Disposition of Assets, Change in..
AQ
04/12IMMUNE PHARMACEUTICALS INC : Change in Directors or Principal Officers, Other Events (form..
AQ
2020Motion for Asset Sale Approved for Immune Pharmaceuticals, Inc.
CI
2020Motion For Case Conversion Approved for Immune Pharmaceuticals, Inc.
CI
2019Motion for Asset Sale Approved for Immune Pharmaceuticals, Inc.
CI
2019Immune Pharmaceuticals, Inc. cancelled the transaction announced on October 9, 2018
CI
2019Motion for Case Conversion or Dismissal Filed for Immune Pharmaceuticals, Inc.
CI
2019Bidding Procedure Approved for Immune Pharmaceuticals, Inc.
CI
2019Motion for Asset Sale Filed by Immune Pharmaceuticals, Inc.
CI
2019Motion for Case Conversion Filed by Immune Pharmaceuticals, Inc.
CI
More news
Chart IMMUNE PHARMACEUTICALS, INC.
Duration : Period :
Immune Pharmaceuticals, Inc. Technical Analysis Chart | IMNPQ | US45254C2008 | MarketScreener
Managers and Directors
Adeel Ahmed-Daudpota President & Chief Executive Officer
Devin J. Shaw Chief Financial Officer
John Zhang Vice President-Research & Development
John A. Neczesny Independent Director
Jeffrey Paley Independent Director
Sector and Competitors
1st jan.Capi. (M$)
IMMUNE PHARMACEUTICALS, INC.-90.00%0
JOHNSON & JOHNSON1.16%420 557
ROCHE HOLDING AG15.70%334 662
PFIZER, INC.42.35%294 114
NOVO NORDISK A/S67.75%247 392
ELI LILLY AND COMPANY50.93%231 027